Salvage Chemotherapy of Vinorelbine Plus Oxaliplatin in Metastatic Triple-negative Breast Cancer:a Prospective Trial

Exclusion Criteria

• •1. Pregnant or lactating women (female patients of child-bearing potential must have a negative serum pregnancy test within 14 days of first day of drug dosing, or, if positive, a pregnancy ruled out by ultrasound)
• •2. Women of child-bearing potential, unwilling to use adequate contraceptive protection during the course of the study
• •3. Treatment with an investigational product within 4 weeks before the first treatment
• •4. Symptomatic central nervous system metastases
• •5. Other active malignancies (including other hematologic malignancies) or other malignancies, except for cured nonmelanoma skin cancer or cervical intraepithelial neoplasia.
• •6. Patient having a history of clinically significant cardiovascular, hepatic, respiratory or renal diseases, clinically significant hematological and endocrinal abnormalities, clinically significant neurological or psychiatric conditions
• •7. Uncontrolled serious infection
• •8. Previous administration of vinorelbine
• •9. Patients with bad compliance